Abstract
Treatment of Relapsed/Refractory Waldenström Macroglobulinemia Patients: Final Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL)
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have